UK markets closed

Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
23.44+0.52 (+2.27%)
As of 11:59AM EDT. Market open.

Guardant Health, Inc.

3100 Hanover Street
Palo Alto, CA 94304
United States
855 698 8887

IndustryDiagnostics & Research
Full-time employees1,793

Key executives

NameTitlePayExercisedYear born
Dr. Helmy Eltoukhy Ph.D.Co-Founder, Co-CEO & Chairman13.66k2.32M1979
Dr. AmirAli Talasaz Ph.D.Co-CEO & Director13.27k2.32M1980
Mr. Michael BellChief Financial Officer1.2MN/A1969
Mr. John G. SaiaChief Legal Officer641.22kN/A1973
Dr. Craig Eagle M.D.Chief Medical Officer2.88MN/A1967
Mr. Christopher FreemanChief Commercial Officer of Oncology Bus.740.23kN/A1974
Mr. Andy AmentSr. VP of OperationsN/AN/AN/A
Darya ChudovaSr. VP of TechnologyN/AN/AN/A
Mr. Kumud KaliaChief Information Officer & COO of OncologyN/AN/AN/A
Ms. Jennifer HigginsVP of Public AffairsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of our portfolio of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Corporate governance

Guardant Health, Inc.’s ISS governance QualityScore as of 1 March 2023 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.